Header

Lung Cancer Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 64 in total

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, ei...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 12-134

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

The primary purpose of the study is to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 13-350

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-III non-small cell lung cancer that...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number:

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and ...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number:

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely remove...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 15-701

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive Triple Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer ...

Diagnosis: Lung Cancer, Breast: Early Stage Disease

Phase: 3

Protocol Number: 16-727

Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 16-459

Afatinib With CT and RT for EGFR-Mutant NSCLC

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Inv...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 11-464

Ponatinib in Advanced NSCLC w/ RET Translocations

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigat...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 13-103

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a muta...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 14-370

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) after one or two prior lines of syst...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 15-387

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhi...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-019

Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer

The purpose of this study is to determine the objective response rate (ORR) in PD-L1+ stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-108

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research stud...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-093

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable o...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-128

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon ...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-374

A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer

The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab alone in people with advanced lung cancer.

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-239

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone re...

Diagnosis: Lung Cancer, Breast: Metastatic

Phase: 2

Protocol Number: 16-216

Pleurectomy/Decortication Followed By Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has m...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-372

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

To estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 14-249

A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities

The purpose of this study is to determine the safety of TAS-120 and determine the most appropriate dose for the subsequent phase 2 safety and efficacy study in patients with advanced solid tumors a...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 14-135

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-055

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that ...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-461

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally the purpose of t...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-322

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-479

A Trial of AP32788 in Non-Small Cell Lung Cancer

The purpose of this phase 1/2 study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of oral AP32788 in patients with non-small cell lung cancer (NSCLC). The trial will be condu...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 16-143

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma

The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory s...

Diagnosis: Solid Tumor/Phase I, Lung Cancer, Brain/Neuro Cancer: Newly Diagnosed

Phase: 1 / 2

Protocol Number: 15-557

Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.

The study determines the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of EGF816 in combination with INC280 and to estimate the preliminary anti-tumor activity of EGF816 in combin...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-233

Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer

This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the cour...

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 15-023

1
<< Previous
'